Digestive System Diseases

633 trials 301 recruiting

Filter these 633 trials by phase, country and sponsor.

Open in Search →

A study looking at how effective and safe AZD7798 is in people with Crohn's disease Ended

2023-510487-12-00 Crohn's Disease 4 2024-11-29
Transmural Healing and Disease Modifying Effect of Guselkumab in Crohn’s Disease Patients Ended

2023-504040-34-01 Crohn’s Disease 5 2024-11-12
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended

2023-508636-61-00 Crohn’s Disease 5 2024-10-24
A Study of Elafibranor in Adults with Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid Ended

2024-510695-20-00 Primary Biliary Cholangitis (PBC) 5 2024-10-15
A Phase 2a/b study of the efficacy and safety of subcutaneous amlitelimab in adults with non-responsive celiac disease Ended

2024-511213-38-00 Coeliac disease 4 2024-10-15
JAK1 inhibitor treatment of inflammatory liver adenomas Ended

2023-505278-13-00 -women with an inflammatory HCA proven at histology and 4 2024-10-01
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in … Ended

2023-506769-67-00 Moderate to Severely Active Ulcerative Colitis 4 2024-09-04
Single arm phase II study of ctDNA-guided encorafenib plus cetuximab retreatment in patients with BRAF V600E mutated mCRC. BRICKET study Ended

2023-509088-26-00 Metastatic colorectal cancer 4 2024-07-22
TGF‐β And PDL‐1 inhibition with Bintrafusp alfa in Esophageal Squamous Cell carcinoma combined with chemoradiation TheRapY (TAPESTRY) Ended

2023-503312-32-00 Esophageal squamous cell carcinoma 4 2024-06-24
Pyridoxine in primary sclerosing cholangitis Ended

2023-505155-47-00 Primary sclerosing cholangitis 4 2024-06-19
A study to evaluate the safety and the activity of S095029 as a part of combination therapy in advanced gastroesophageal junction/gastric ca… Ended

2023-507995-33-00 MSI-H/dMMR Gastric cancer 9 2024-05-23
Subcutaneous infliximab after a previous intravenous dose optimization (AMARETTO trial) Ended

2023-508166-15-00 Ulcerative colitis (UC), Inflammatory bowel disease typ 6 2024-04-29
A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Pati… Ended

2022-502043-35-01 Advanced Biliary Tract Cancers 5 2024-04-24
Randomised, placebo-controlled Phase II proof of concept study of efficacy and safety of a novel rifamycin SV in situ gelling rectal solutio… Ended

2023-506917-23-00 patients with mild to moderate left-sided ulcerative co 4 2024-04-19
The efficacy of aprepitant for the prevention of postoperative nausea and vomiting after bariatric surgery. Ended

2023-508849-40-00 Postoperative nausea and vomiting 6 2024-04-11
A Study of Mirikizumab (LY3074828) in Pediatric Participants with Crohn’s Disease (AMAY) Ended

2024-511472-32-00 Crohn's Disease 5 2024-03-12
PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed… Ended

2023-505972-32-00 locally advanced anal squamous cell carcinoma 5 2024-02-26
An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative… Ended

2024-511963-28-00 Neoadjuvant therapy in locally-advanced rectal cancer 3 2023-12-19
A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease. Ended

2022-502789-26-01 Fibrostenotic Crohn’s Disease 4 2023-11-03
Early versus postponed supplementary parenteral nutrition after major emergency abdominal surgery Ended

2023-505378-14-00 Major emergency abdominal surgery 6 2023-10-18
A clinical study to assess how safe and effective it is for subjects with hepatocellular carcinoma (HCC) to receive radiation therapy with T… Ended

2023-508945-41-00 Hepatocellular Carcinoma 4 2023-10-11
A Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis Ended

2024-510627-20-00 Non-alcoholic Steatohepatitis (NASH) Cirrhosis 5 2023-07-28
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn’s Disease Ended

2024-515027-11-00 Crohn’s disease 4 2023-06-29
Dose-finding study of SAR443122 in adult participants with ulcerative colitis Ended

2022-500290-14-01 Colitis ulcerative 4 2023-05-11